Achilles Therapeutics Pl-adr (ACHL)
$0.7744
Insights on Achilles Therapeutics Pl-adr
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 58.1%
Performance
- $0.74$0.80$0.77
3.9%
Downside
Day's Volatility :7.5%
Upside
3.75%
- $0.74$1.76$0.77
3.9%
Downside
52 Weeks Volatility :57.95%
Upside
56.25%
Returns
| Period | Achilles Therapeutics Pl-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -19.33% | 0.5% | 0.0% |
6 Months | -10.47% | 11.7% | 0.0% |
1 Year | -5.56% | 6.2% | 2.2% |
3 Years | -89.11% | 13.5% | -23.0% |
Highlights
Market Capitalization | 32.3M |
Book Value | $3.47 |
Earnings Per Share (EPS) | -1.74 |
Wall Street Target Price | 2.83 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.61% |
Return On Equity TTM | -41.05% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -70.4M |
Diluted Eps TTM | -1.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.06 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.47 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 265.44%
Technicals Summary
Sell
Neutral
Buy
Achilles Therapeutics Pl-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Achilles Therapeutics Pl-adr | -37.55% | -10.47% | -5.56% | -89.11% | -89.11% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Achilles Therapeutics Pl-adr | 0.17 | NA | NA | -1.06 | -0.41 | -0.25 | NA | 3.47 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Achilles Therapeutics Pl-adr | Buy | $32.3M | -89.11% | 0.17 | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Syncona Portfolio Ltd.
27.19%FCPM III SERVICES BV
5.86%Artal Group S A
5.53%Baker Bros Advisors LP
5.16%Redmile Group, LLC
3.94%Point72 Asset Management, L.P.
3.47%
Company Information
achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
Organization | Achilles Therapeutics Pl-adr |
Employees | 204 |
CEO | Dr. Iraj Ali Ph.D. |
Industry | Healthcare |
